surpass cvot tirzepatide C. Michael Gibson MD on X: "SURPASS-CVOT trial: was non-inferior to dulaglutide and superior to putative placebo for reducing the composite of CV death/HF events in patients with T2D and ASCVD. # Tirzepatide in SURPASS‑CVOT: Favorable Cardiovascular

Compare that to the 25% lean mass loss seen in clinical trials without these interventions

The move is an escalation of the battle between Lilly and Novo Nordisk in the fast-growing obesity drugs market, where Zepbound is in a head-to-head contest with the latter's Wegovy (semaglutide) brand

Try: 3 modest meals and 12 healthy snacks per day Chewing slowly and stopping when you feel comfortably full 4

Genetic predispositions in peptide signaling pathways (GIPR, MC4R, FTO variants) can support more informed conversations with providers about expected dose ranges and titration pace, though they do not predict exact individual response